[go: up one dir, main page]

CY1109468T1 - Χρησεις ανταγωνιστων της il-23. σχετικα αντιδραστηρια - Google Patents

Χρησεις ανταγωνιστων της il-23. σχετικα αντιδραστηρια

Info

Publication number
CY1109468T1
CY1109468T1 CY20091101030T CY091101030T CY1109468T1 CY 1109468 T1 CY1109468 T1 CY 1109468T1 CY 20091101030 T CY20091101030 T CY 20091101030T CY 091101030 T CY091101030 T CY 091101030T CY 1109468 T1 CY1109468 T1 CY 1109468T1
Authority
CY
Cyprus
Prior art keywords
competitors
related reagents
methods
reagents
tumors
Prior art date
Application number
CY20091101030T
Other languages
English (en)
Inventor
Martin Oft
Terrill K Mcclanahan
Original Assignee
Schering Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corporation filed Critical Schering Corporation
Publication of CY1109468T1 publication Critical patent/CY1109468T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Παρέχονται μέθοδοι θεραπείας για όγκους. Ειδικότερα, παρέχονται μέθοδοι για ρύθμιση της δραστηριότητας ενός μορίου κυτοκίνης και του υποδοχέα της.
CY20091101030T 2003-03-10 2009-10-06 Χρησεις ανταγωνιστων της il-23. σχετικα αντιδραστηρια CY1109468T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45367203P 2003-03-10 2003-03-10
EP04718824A EP1601694B1 (en) 2003-03-10 2004-03-09 Uses of il-23 antagonists; related reagents

Publications (1)

Publication Number Publication Date
CY1109468T1 true CY1109468T1 (el) 2014-08-13

Family

ID=32990805

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101030T CY1109468T1 (el) 2003-03-10 2009-10-06 Χρησεις ανταγωνιστων της il-23. σχετικα αντιδραστηρια

Country Status (23)

Country Link
US (4) US7282204B2 (el)
EP (2) EP1601694B1 (el)
JP (4) JP4605798B2 (el)
CN (1) CN1759123B (el)
AT (1) ATE440864T1 (el)
AU (2) AU2004219625B9 (el)
BR (1) BRPI0408247A (el)
CA (1) CA2518262C (el)
CL (1) CL2004000467A1 (el)
CY (1) CY1109468T1 (el)
DE (1) DE602004022781D1 (el)
DK (1) DK1601694T3 (el)
ES (1) ES2330220T3 (el)
HK (1) HK1076477A1 (el)
MX (1) MXPA05009717A (el)
NO (1) NO20054630D0 (el)
NZ (2) NZ541898A (el)
PL (1) PL1601694T3 (el)
PT (1) PT1601694E (el)
SI (1) SI1601694T1 (el)
TW (2) TWI439285B (el)
WO (1) WO2004081190A2 (el)
ZA (1) ZA200506879B (el)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CN101824088B (zh) * 2002-10-30 2012-05-30 健泰科生物技术公司 Il-17产生的抑制
CA2518262C (en) * 2003-03-10 2014-05-06 Schering Corporation Uses of il-23 agonists and antagonists; related reagents
CN101052726A (zh) * 2003-05-09 2007-10-10 森托科尔公司 IL－23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途
JP4903061B2 (ja) * 2004-02-17 2012-03-21 シェーリング コーポレイション Ｉｌ−２３活性を調節する方法；関連する試薬
JP2007527246A (ja) * 2004-03-05 2007-09-27 アーケミックス コーポレイション ヒトｉｌ−１２サイトカインファミリーに対するアプタマーおよび自己免疫疾患の治療剤としてのそれらの使用
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
US7820168B2 (en) 2004-12-20 2010-10-26 Schering Corporation Treatment of diabetes using antibodies to IL-23, IL-23 receptor and IL-17
AU2012258409B2 (en) * 2005-06-30 2016-01-07 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
CN101252951B (zh) 2005-06-30 2011-12-21 森托科尔公司 抗il-23抗体、组合物、方法和用途
AU2006265898A1 (en) * 2005-06-30 2007-01-11 Archemix Corp. Polynucleotides and polypeptides of the IL-12 family of cytokines
ES2347690T3 (es) * 2005-08-25 2010-11-03 Eli Lilly And Company Anticuerpos anti-il-23.
CA2620802A1 (en) 2005-08-31 2007-03-08 Schering Corporation Engineered anti-il-23 antibodies
ES2333260T3 (es) 2005-09-01 2010-02-18 Schering Corporation Uso de antagonistas de il-23 e il-17 para tratar la enfermedad inflamatoria ocular autoinmunologica.
ES2517420T3 (es) * 2005-12-29 2014-11-03 Janssen Biotech, Inc. Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
EP2044118A2 (en) 2006-06-13 2009-04-08 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
EP1882699A1 (en) * 2006-07-27 2008-01-30 Heinfried Radeke Regulation of interleukin-23
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
PL2059534T3 (pl) 2007-02-23 2012-09-28 Merck Sharp & Dohme Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
US20100111966A1 (en) 2007-02-23 2010-05-06 Schering Corporation Engineered anti-il-23p19 antibodies
NZ597915A (en) * 2007-02-28 2013-08-30 Merck Sharp & Dohme Combination therapy for treatment of immune disorders
CN101675076B (zh) 2007-02-28 2013-09-18 默沙东公司 工程化的抗il-23r抗体
CN101990547A (zh) * 2007-07-06 2011-03-23 瓦勒瑞萨欣Hsj有限合伙公司 Il-23受体拮抗剂以及其应用
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
EP2216047A4 (en) 2007-10-24 2011-12-28 Nat Univ Corp Tokyo Med & Dent Regulator for signaling of toll-like receptor, which comprises cathepsin inhibitor as active ingredient
SG190626A1 (en) 2008-05-05 2013-06-28 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
US20110158992A1 (en) * 2008-08-27 2011-06-30 Schering Corporation Engineered Anti-IL-23R Antibodies
US20110183859A1 (en) * 2008-09-25 2011-07-28 The United States Of America, As Represented By The Secretary, Inflammatory genes and microrna-21 as biomarkers for colon cancer prognosis
EP2350316B1 (en) * 2008-10-20 2014-04-16 ValiPharma Methods and uses involving genetic aberrations of nav3 and aberrant expression of multiple genes
CA2757237A1 (en) * 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
BRPI1014544B8 (pt) 2009-05-05 2021-05-25 Novimmune Sa anticorpo anti-il-17f monoclonal totalmente humano isolado e composição farmacêutica compreendendo o mesmo
EP2456787A4 (en) * 2009-07-24 2013-01-30 Univ Leland Stanford Junior CYTOKIN COMPOSITIONS AND METHOD FOR THEIR USE
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
USRE49026E1 (en) 2011-06-14 2022-04-12 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
PL3326649T3 (pl) 2012-05-03 2022-04-25 Boehringer Ingelheim International Gmbh Przeciwciała anty-il-23p19
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
JP2017524359A (ja) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
MY192824A (en) 2014-09-03 2022-09-12 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
US11279754B2 (en) 2015-03-11 2022-03-22 Rush University Medical Center Compositions and methods for treating cancer
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
BR112019022873A8 (pt) 2017-05-02 2023-04-11 Merck Sharp & Dohme Formulação, e, vaso ou dispositivo de injeção.
WO2019171252A1 (en) 2018-03-05 2019-09-12 Janssen Biotech, Inc. Methods of treating crohn's disease with anti-il23 specific antibody
JP2022513094A (ja) 2018-11-20 2022-02-07 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ－２３特異的抗体で乾癬を治療する安全かつ有効な方法
CN113874073A (zh) 2019-05-23 2021-12-31 詹森生物科技公司 用针对IL-23和TNFα的抗体的联合疗法治疗炎性肠病的方法
BR112022020826A2 (pt) * 2020-04-17 2022-11-29 Univ Leland Stanford Junior Polipeptídeos il-12 e il-23 projetados e usos dos mesmos
US12258393B2 (en) 2020-05-21 2025-03-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
US5767063A (en) 1991-03-29 1998-06-16 Genentech, Inc. Human IL-8 receptor and antibodies thereto
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6060284A (en) * 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
JP4505166B2 (ja) * 1999-09-09 2010-07-21 シェーリング コーポレイション 哺乳動物インターロイキン−１２ｐ４０およびインターロイキンｂ３０、その組成物、抗体、薬学的組成物における使用
KR100869621B1 (ko) * 2000-05-10 2008-11-21 쉐링 코포레이션 포유류 수용체 단백질, 관련 시약 및 방법
CA2425169A1 (en) 2000-10-06 2002-04-11 Immunex Corporation Hematopoietin receptors hpr1 and hpr2
AU2002314825A1 (en) * 2001-05-30 2002-12-09 Centocor, Inc. Anti-p40 immunoglobulin derived proteins, compositions, methods and uses
CA2518262C (en) * 2003-03-10 2014-05-06 Schering Corporation Uses of il-23 agonists and antagonists; related reagents

Also Published As

Publication number Publication date
US20100003251A1 (en) 2010-01-07
ATE440864T1 (de) 2009-09-15
CA2518262C (en) 2014-05-06
US20120034219A1 (en) 2012-02-09
CN1759123A (zh) 2006-04-12
NO20054630L (no) 2005-10-07
US20080057058A1 (en) 2008-03-06
SI1601694T1 (sl) 2010-01-29
EP1601694B1 (en) 2009-08-26
TWI357336B (en) 2012-02-01
CL2004000467A1 (es) 2005-05-06
ZA200506879B (en) 2006-05-31
US8034341B2 (en) 2011-10-11
EP2108658B1 (en) 2016-06-08
TW201141521A (en) 2011-12-01
EP2108658A1 (en) 2009-10-14
JP4605798B2 (ja) 2011-01-05
AU2004219625B9 (en) 2010-12-23
JP2011032275A (ja) 2011-02-17
NZ567860A (en) 2009-11-27
NZ541898A (en) 2008-07-31
JP2006520781A (ja) 2006-09-14
AU2004219625B2 (en) 2010-08-19
BRPI0408247A (pt) 2006-03-01
DE602004022781D1 (de) 2009-10-08
JP2007197453A (ja) 2007-08-09
EP1601694A2 (en) 2005-12-07
WO2004081190A2 (en) 2004-09-23
AU2010212372B2 (en) 2012-12-20
TWI439285B (zh) 2014-06-01
PT1601694E (pt) 2009-12-03
JP2014005286A (ja) 2014-01-16
AU2004219625A1 (en) 2004-09-23
CA2518262A1 (en) 2004-09-23
CN1759123B (zh) 2011-04-13
MXPA05009717A (es) 2005-10-18
HK1076477A1 (en) 2006-01-20
AU2010212372A1 (en) 2010-09-09
PL1601694T3 (pl) 2010-02-26
US7282204B2 (en) 2007-10-16
US20040223969A1 (en) 2004-11-11
TW200505479A (en) 2005-02-16
DK1601694T3 (da) 2009-12-14
ES2330220T3 (es) 2009-12-07
NO20054630D0 (no) 2005-10-07
WO2004081190A3 (en) 2005-02-03

Similar Documents

Publication Publication Date Title
CY1109468T1 (el) Χρησεις ανταγωνιστων της il-23. σχετικα αντιδραστηρια
CY1108645T1 (el) Θεραπεια και διαγνωση νεοπλασματων χρησιμοποιωντας θυμικη στρωματικη λεμφοποιητινη
NO20053817D0 (no) Preparater og fremgangsmater for antiviral kombinasjonsterapi.
CY1115441T1 (el) Αναστολεις p38 και μεθοδοι χρησης αυτων
NO20064193L (no) fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser
CY1112946T1 (el) 4-υδροξυβενζομορφανια
ATE515514T1 (de) Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
BRPI0417823A (pt) métodos para uso de bifidobactérias probióticas para animais de estimação
CY1112862T1 (el) Θραυσματα μονοσθενους αντισωματος χρησιμα ως θεραπευτικα
BR0215924B1 (pt) dispositivo para osteossìntese.
NO20064194L (no) Fremgangsmate for a modulere IL-23-aktivitet, beslektede reagenser
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
WO2003104425A3 (en) NEW STABLE ANTI-CD22 ANTIBODIES
CY1113083T1 (el) Ασβεστιολυτικες ενωσεις
BR0209307B1 (pt) aparelho para uso em bombas.
NO20053986D0 (no) Sammensetninger og fremgangsmater for a behandle cancer anvendende IGSF9 og LIV-1.
NO20053903D0 (no) Nukleotidlipidesterderivater.
ITMI20022389A1 (it) Farmaci per le disfunzioni sessuali.
ITTO20021081A1 (it) Procedimento e dispositivo per la moltiplicazione in virgola mobile, relativo prodotto informatico.
DK1646649T3 (da) Macc1-polypeptid og dets anvendelse til tumordiagnostik og tumorterapi.
NO20053189D0 (no) HVC-kombinasjonsterapi.
IS7441A (is) Peptíðdeformýlasatálmar
ITRM20030283A1 (it) Mezzi terapeutici e diagnostici per i papillomi.
NL1021524A1 (nl) Menginrichting.
DE60232650D1 (de) Peptiddeformylaseinhibitoren